Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.64 USD | -2.22% | -13.44% | -16.98% |
Mar. 07 | Lumos Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 07 | Transcript : Lumos Pharma, Inc., 2023 Earnings Call, Mar 07, 2024 |
Financials (USD)
Sales 2024 * | 10.51M | Sales 2025 * | 10.3M | Capitalization | 21.4M |
---|---|---|---|---|---|
Net income 2024 * | -35M | Net income 2025 * | -39M | EV / Sales 2024 * | 2.04 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.08 x |
P/E ratio 2024 * |
-0.94
x | P/E ratio 2025 * |
-1.38
x | Employees | 33 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 62.88% |
Latest transcript on Lumos Pharma, Inc.
1 day | -2.22% | ||
1 week | -13.44% | ||
Current month | -13.44% | ||
1 month | -10.81% | ||
3 months | -13.44% | ||
6 months | -16.19% | ||
Current year | -16.98% |
Managers | Title | Age | Since |
---|---|---|---|
Richard Hawkins
CEO | Chief Executive Officer | 75 | 10-08-31 |
Lori Lawley
DFI | Director of Finance/CFO | 40 | 20-02-29 |
John McKew
PSD | President | 59 | 15-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Lota Zoth
BRD | Director/Board Member | 64 | 12-10-31 |
Richard Hawkins
CEO | Chief Executive Officer | 75 | 10-08-31 |
Kevin Lalande
BRD | Director/Board Member | 51 | 13-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-18 | 2.64 | -2.22% | 13,189 |
24-03-15 | 2.7 | +1.89% | 33,735 |
24-03-14 | 2.65 | -10.77% | 56,507 |
24-03-13 | 2.97 | -1.66% | 6,657 |
24-03-12 | 3.02 | -0.98% | 36,001 |
Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.98% | 21.4M | |
+9.72% | 46.21B | |
+34.55% | 40.04B | |
+4.84% | 39.92B | |
-9.43% | 28.33B | |
+17.47% | 27.43B | |
-22.99% | 18.57B | |
+10.88% | 13.46B | |
+27.53% | 12.02B | |
-6.84% | 11.3B |